Trial · NCT01321723
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| % Change From Baseline BMD in L1-L4 Axial Lumbar Spine at Week 24 | Forsteo (Teriparatide) | 5.07 | Standard Deviation 3.543 | percentage of change | |
| % Change From Baseline BMD in L1-L4 Axial Lumbar Spine at Week 24 | PTH Analog Tablets | 2.21 | Standard Deviation 2.503 | percentage of change | |
| % Change From Baseline BMD in L1-L4 Axial Lumbar Spine at Week 24 | Placebo | -0.17 | Standard Deviation 2.739 | percentage of change | |
| Number of Participants With AEs as a Measure of Safety and Tolerability | Forsteo (Teriparatide) | 23 | participants | ||
| Number of Participants With AEs as a Measure of Safety and Tolerability | PTH Analog Tablets | 30 | participants | ||
| Number of Participants With AEs as a Measure of Safety and Tolerability | Placebo | 21 | participants | ||
| % Change From Baseline in Bone Resorption Marker (CTx-1) at Week 24 | Forsteo (Teriparatide) | 113.32 | Standard Deviation 102.932 | percentage of change | |
| % Change From Baseline in Bone Resorption Marker (CTx-1) at Week 24 | PTH Analog Tablets | 12.72 | Standard Deviation 36.547 | percentage of change | |
| % Change From Baseline in Bone Resorption Marker (CTx-1) at Week 24 | Placebo | 15.13 | Standard Deviation 23.940 | percentage of change | |
| Systemic Absorption of PTH at Week 24 | Forsteo (Teriparatide) | 152 | Standard Deviation 65.7 | pg* hr/mL | |
| Systemic Absorption of PTH at Week 24 | PTH Analog Tablets | 165 | Standard Deviation 180 | pg* hr/mL | |
| % Change From Baseline in Bone Formation Marker (P1NP) at Week 24 | Forsteo (Teriparatide) | 210.07 | Standard Deviation 202.613 | percentage of change | |
| % Change From Baseline in Bone Formation Marker (P1NP) at Week 24 | PTH Analog Tablets | 12.05 | Standard Deviation 37.055 | percentage of change | |
| % Change From Baseline in Bone Formation Marker (P1NP) at Week 24 | Placebo | -1.75 | Standard Deviation 27.459 | percentage of change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01321723/results